ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,937 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryLausannefondation Innovative Medicines for Tuberculosis (iM4TB)
fondation Innovative Medicines for Tuberculosis (iM4TB) Logo
Verified· 2 sourcesTrust Score
Summary

About the company

The core activity of iM4TB is the development of innovative medicines to combat tuberculosis. The company researches and develops new treatment methods and agents to eliminate tuberculosis.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
✓ Offered4
Development of New Tuberculosis Medicines
Development of better and faster-acting medicines against tuberculosis, including preclinical and clinical development, to enable affordable TB treatment.
Development of Tuberculosis Treatment Regimens (ERA4TB)
Accelerating the development of new tuberculosis treatment regimens in a public-private consortium, with a parallel pipeline and preparation for a Phase II assessment.
Development of the Active Substance PBTZ169 (Macozinone)
Preclinical and clinical development of the TB active substance candidate PBTZ169, including Phase Ia and Phase Ib studies as well as preparation for further development steps.
Funding and Bridging Support for TB Research
Financial support for preclinical and clinical development phases to move promising tuberculosis molecules through the early development stage.
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

fondation Innovative Medicines for Tuberculosis (iM4TB)

Trust & reputation

ranQ Trust Score of fondation Innovative Medicines for Tuberculosis (iM4TB): 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 54% · As of October 2026

Without public customer reviews the score stays capped.

fondation Innovative Medicines for Tuberculosis (iM4TB) has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
fondation Innovative Medicines for Tuberculosis (iM4TB) scores 85.4 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.92.512%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.70.07%
fondation Innovative Medicines for Tuberculosis (iM4TB) scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
fondation Innovative Medicines for Tuberculosis (iM4TB) scores 94.3 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.94.34%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

fondation Innovative Medicines for Tuberculosis (iM4TB) reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once fondation Innovative Medicines for Tuberculosis (iM4TB) has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

fondation Innovative Medicines for Tuberculosis (iM4TB) in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank fondation Innovative Medicines for Tuberculosis (iM4TB) by reviews, experience and specialisations.

Is this your company?

Claim the company profile of fondation Innovative Medicines for Tuberculosis (iM4TB) to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

EPFL
1015 Lausanne
Opening hours
Mon
09:00 - 17:00
Tue
09:00 - 17:00
Wed
09:00 - 17:00
Thu
09:00 - 17:00
Fri
09:00 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Foundation
UID
CHE-270.892.523
Founded
2014 · 12 years
Last commercial register change
February 17, 2026
Employees
11 to 20
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.97.06%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    AI
    AC Immune SA
    Lausanne
    FE
    FONDATION EUROVACC
    Lausanne
    FV
    Ferring Ventures SA
    St-Prex
    FP
    Ferring Pharmaceuticals SA
    St-Prex
    FI
    Ferring International Center SA
    St-Prex
    PS
    Pharmotech SA
    Eysins
    IB
    Incyte Biosciences International Sàrl
    Morges
    OT
    Onward Therapeutics SA
    Epalinges